KDR and gastric cancer: Based on the observed response in the REGARD and RAINBOW study (12, 13), the US Food and Drug Administration (FDA) granted the use of ramucirumab(an anti-vascular endothelial growth factor receptor-2 agent, anti-VEGFR-2) with paclitaxel or ramucirumab monotherapy for recurrent locally advanced or metastatic GC who progressed on or after two or more previous lines of therapy.